The Experts below are selected from a list of 5712 Experts worldwide ranked by ideXlab platform
Mamadou Lelenta - One of the best experts on this subject based on the ideXlab platform.
-
Development and validation of an epitope-blocking ELISA using an anti-haemagglutinin monoclonal antibody for specific detection of antibodies in sheep and goat sera directed against peste des petits ruminants virus
Archives of Virology, 2018Co-Authors: Sanne Charles Bodjo, Jean-de-dieu Baziki, Nick Nwankpa, Ethel Chitsungo, Yao Mathurin Koffi, Emmanuel Couacy-hymann, Mariame Diop, Daniel Gizaw, Idris Badri Adam Tajelser, Mamadou LelentaAbstract:Peste des petits ruminants (PPR) is a contagious and economically important disease affecting production of small ruminants (i.e., sheep and goats). Taking into consideration the lessons learnt from the Global Rinderpest Eradication Programme (GREP), PPR is now targeted by the international Veterinary community as the next animal disease to be eradicated. To support the African continental programme for the control of PPR, the Pan African Veterinary Vaccine Centre of the African Union (AU-PANVAC) is developing diagnostics tools. Here, we describe the development of a blocking enzyme-linked immunosorbent assay (bELISA) that allows testing of a large number of samples for specific detection of antibodies directed against PPR virus in sheep and goat sera. The PPR bELISA uses an anti-haemagglutinin (H) monoclonal antibody (MAb) as a competitor antibody, and tests results are interpreted using the percentage of inhibition (PI) of MAb binding generated by the serum sample. PI values below or equal to 18% (PI ≤ 18%) are negative, PI values greater than or equal to 25% (PI ≥ 25%) are positive, and PI values greater than 18% and below 25% are doubtful. The diagnostic specificity (DSp) and diagnostic sensitivity (DSe) were found to be 100% and 93.74%, respectively. The H-based PPR-bELISA showed good correlation with the virus neutralization test (VNT), the gold standard test, with a kappa value of 0.947. The H-based PPR-bELISA is more specific than the commercial kit ID Screen® PPR Competition (N-based PPR-cELISA) from IDvet (France), but the commercial kit is slightly more sensitive than the H-based PPR-bELISA. The validation process also indicated good repeatability and reproducibility of the H-based PPR-bELISA, making this new test a suitable tool for the surveillance and sero-monitoring of the vaccination campaign.
-
Development and validation of an epitope-blocking ELISA using an anti-haemagglutinin monoclonal antibody for specific detection of antibodies in sheep and goat sera directed against peste des petits ruminants virus
Archives of Virology, 2018Co-Authors: Sanne Charles Bodjo, Jean-de-dieu Baziki, Nick Nwankpa, Ethel Chitsungo, Yao Mathurin Koffi, Emmanuel Couacy-hymann, Mariame Diop, Daniel Gizaw, Idris Badri Adam Tajelser, Mamadou LelentaAbstract:Peste des petits ruminants (PPR) is a contagious and economically important disease affecting production of small ruminants (i.e., sheep and goats). Taking into consideration the lessons learnt from the Global Rinderpest Eradication Programme (GREP), PPR is now targeted by the international Veterinary community as the next animal disease to be eradicated. To support the African continental programme for the control of PPR, the Pan African Veterinary Vaccine Centre of the African Union (AU-PANVAC) is developing diagnostics tools. Here, we describe the development of a blocking enzyme-linked immunosorbent assay (bELISA) that allows testing of a large number of samples for specific detection of antibodies directed against PPR virus in sheep and goat sera. The PPR bELISA uses an anti-haemagglutinin (H) monoclonal antibody (MAb) as a competitor antibody, and tests results are interpreted using the percentage of inhibition (PI) of MAb binding generated by the serum sample. PI values below or equal to 18% (PI ae 18%) are negative, PI values greater than or equal to 25% (PI ae 25%) are positive, and PI values greater than 18% and below 25% are doubtful. The diagnostic specificity (DSp) and diagnostic sensitivity (DSe) were found to be 100% and 93.74%, respectively. The H-based PPR-bELISA showed good correlation with the virus neutralization test (VNT), the gold standard test, with a kappa value of 0.947. The H-based PPR-bELISA is more specific than the commercial kit ID ScreenA (R) PPR Competition (N-based PPR-cELISA) from IDvet (France), but the commercial kit is slightly more sensitive than the H-based PPR-bELISA. The validation process also indicated good repeatability and reproducibility of the H-based PPR-bELISA, making this new test a suitable tool for the surveillance and sero-monitoring of the vaccination campaign.
Thomas P. Monath - One of the best experts on this subject based on the ideXlab platform.
-
RESEARCH Efficacy of Killed Virus Vaccine, Live Attenuated Chimeric Virus Vaccine, and Passive Immunization for Prevention of West Nile virus Encephalitis in Hamster Model
2013Co-Authors: Robert B. Tesh, Juan Arroyo, Hilda Guzman, Shu-yuan Xiao, Thomas P. MonathAbstract:Results of experiments evaluating the efficacy of three immunization strategies for the prevention of West Nile virus (WNV) encephalitis are reported. Immunization strategies evaluated included a killed virus Veterinary Vaccine, a live attenuated chimeric virus Vaccine candidate, and passive immunization with WNVimmune serum; all were tested by using a hamster model of the disease. Each product protected the animals from clinical illness and death when challenged with a hamster-virulent wild-type WNV strain 1 month after initial immunization. The live attenuated chimeric virus Vaccine candidate induced the highest humoral antibody responses, as measured by hemagglutination inhibition, complement fixation, and plaque reduction neutralization tests. Although the duration of protective immunity was not determined in this study, our preliminary results and the cumulative experience of other virus Vaccines suggest that the live attenuated chimeric virus provides the longest lasting immunity. A fter the appearance of West Nile virus (WNV) in North America and the resulting human and equine cases of encephalitis, considerable efforts have focused on developing Vaccines against this emerging viral pathogen. A number of different WNV Vaccine candidates have been recently described and are now in various stages of testing (1–4). A formalin-inactivated Veterinary Vaccine (West Nile Virus Vaccine
-
efficacy of killed virus Vaccine live attenuated chimeric virus Vaccine and passive immunization for prevention of west nile virus encephalitis in hamster model
Emerging Infectious Diseases, 2002Co-Authors: Robert B. Tesh, Juan Arroyo, Hilda Guzman, Shu-yuan Xiao, Amelia Travassos P A Da Rosa, Thomas P. MonathAbstract:Results of experiments evaluating the efficacy of three immunization strategies for the prevention of West Nile virus (WNV) encephalitis are reported. Immunization strategies evaluated included a killed virus Veterinary Vaccine, a live attenuated chimeric virus Vaccine candidate, and passive immunization with WNVimmune serum; all were tested by using a hamster model of the disease. Each product protected the animals from clinical illness and death when challenged with a hamster-virulent wild-type WNV strain 1 month after initial immunization. The live attenuated chimeric virus Vaccine candidate induced the highest humoral antibody responses, as measured by hemagglutination inhibition, complement fixation, and plaque reduction neutralization tests. Although the duration of protective immunity was not determined in this study, our preliminary results and the cumulative experience of other virus Vaccines suggest that the live attenuated chimeric virus provides the longest lasting immunity. fter the appearance of West Nile virus (WNV) in North America and the resulting human and equine cases of
Sanne Charles Bodjo - One of the best experts on this subject based on the ideXlab platform.
-
Development and validation of an epitope-blocking ELISA using an anti-haemagglutinin monoclonal antibody for specific detection of antibodies in sheep and goat sera directed against peste des petits ruminants virus
Archives of Virology, 2018Co-Authors: Sanne Charles Bodjo, Jean-de-dieu Baziki, Nick Nwankpa, Ethel Chitsungo, Yao Mathurin Koffi, Emmanuel Couacy-hymann, Mariame Diop, Daniel Gizaw, Idris Badri Adam Tajelser, Mamadou LelentaAbstract:Peste des petits ruminants (PPR) is a contagious and economically important disease affecting production of small ruminants (i.e., sheep and goats). Taking into consideration the lessons learnt from the Global Rinderpest Eradication Programme (GREP), PPR is now targeted by the international Veterinary community as the next animal disease to be eradicated. To support the African continental programme for the control of PPR, the Pan African Veterinary Vaccine Centre of the African Union (AU-PANVAC) is developing diagnostics tools. Here, we describe the development of a blocking enzyme-linked immunosorbent assay (bELISA) that allows testing of a large number of samples for specific detection of antibodies directed against PPR virus in sheep and goat sera. The PPR bELISA uses an anti-haemagglutinin (H) monoclonal antibody (MAb) as a competitor antibody, and tests results are interpreted using the percentage of inhibition (PI) of MAb binding generated by the serum sample. PI values below or equal to 18% (PI ≤ 18%) are negative, PI values greater than or equal to 25% (PI ≥ 25%) are positive, and PI values greater than 18% and below 25% are doubtful. The diagnostic specificity (DSp) and diagnostic sensitivity (DSe) were found to be 100% and 93.74%, respectively. The H-based PPR-bELISA showed good correlation with the virus neutralization test (VNT), the gold standard test, with a kappa value of 0.947. The H-based PPR-bELISA is more specific than the commercial kit ID Screen® PPR Competition (N-based PPR-cELISA) from IDvet (France), but the commercial kit is slightly more sensitive than the H-based PPR-bELISA. The validation process also indicated good repeatability and reproducibility of the H-based PPR-bELISA, making this new test a suitable tool for the surveillance and sero-monitoring of the vaccination campaign.
-
Development and validation of an epitope-blocking ELISA using an anti-haemagglutinin monoclonal antibody for specific detection of antibodies in sheep and goat sera directed against peste des petits ruminants virus
Archives of Virology, 2018Co-Authors: Sanne Charles Bodjo, Jean-de-dieu Baziki, Nick Nwankpa, Ethel Chitsungo, Yao Mathurin Koffi, Emmanuel Couacy-hymann, Mariame Diop, Daniel Gizaw, Idris Badri Adam Tajelser, Mamadou LelentaAbstract:Peste des petits ruminants (PPR) is a contagious and economically important disease affecting production of small ruminants (i.e., sheep and goats). Taking into consideration the lessons learnt from the Global Rinderpest Eradication Programme (GREP), PPR is now targeted by the international Veterinary community as the next animal disease to be eradicated. To support the African continental programme for the control of PPR, the Pan African Veterinary Vaccine Centre of the African Union (AU-PANVAC) is developing diagnostics tools. Here, we describe the development of a blocking enzyme-linked immunosorbent assay (bELISA) that allows testing of a large number of samples for specific detection of antibodies directed against PPR virus in sheep and goat sera. The PPR bELISA uses an anti-haemagglutinin (H) monoclonal antibody (MAb) as a competitor antibody, and tests results are interpreted using the percentage of inhibition (PI) of MAb binding generated by the serum sample. PI values below or equal to 18% (PI ae 18%) are negative, PI values greater than or equal to 25% (PI ae 25%) are positive, and PI values greater than 18% and below 25% are doubtful. The diagnostic specificity (DSp) and diagnostic sensitivity (DSe) were found to be 100% and 93.74%, respectively. The H-based PPR-bELISA showed good correlation with the virus neutralization test (VNT), the gold standard test, with a kappa value of 0.947. The H-based PPR-bELISA is more specific than the commercial kit ID ScreenA (R) PPR Competition (N-based PPR-cELISA) from IDvet (France), but the commercial kit is slightly more sensitive than the H-based PPR-bELISA. The validation process also indicated good repeatability and reproducibility of the H-based PPR-bELISA, making this new test a suitable tool for the surveillance and sero-monitoring of the vaccination campaign.
Robert B. Tesh - One of the best experts on this subject based on the ideXlab platform.
-
RESEARCH Efficacy of Killed Virus Vaccine, Live Attenuated Chimeric Virus Vaccine, and Passive Immunization for Prevention of West Nile virus Encephalitis in Hamster Model
2013Co-Authors: Robert B. Tesh, Juan Arroyo, Hilda Guzman, Shu-yuan Xiao, Thomas P. MonathAbstract:Results of experiments evaluating the efficacy of three immunization strategies for the prevention of West Nile virus (WNV) encephalitis are reported. Immunization strategies evaluated included a killed virus Veterinary Vaccine, a live attenuated chimeric virus Vaccine candidate, and passive immunization with WNVimmune serum; all were tested by using a hamster model of the disease. Each product protected the animals from clinical illness and death when challenged with a hamster-virulent wild-type WNV strain 1 month after initial immunization. The live attenuated chimeric virus Vaccine candidate induced the highest humoral antibody responses, as measured by hemagglutination inhibition, complement fixation, and plaque reduction neutralization tests. Although the duration of protective immunity was not determined in this study, our preliminary results and the cumulative experience of other virus Vaccines suggest that the live attenuated chimeric virus provides the longest lasting immunity. A fter the appearance of West Nile virus (WNV) in North America and the resulting human and equine cases of encephalitis, considerable efforts have focused on developing Vaccines against this emerging viral pathogen. A number of different WNV Vaccine candidates have been recently described and are now in various stages of testing (1–4). A formalin-inactivated Veterinary Vaccine (West Nile Virus Vaccine
-
efficacy of killed virus Vaccine live attenuated chimeric virus Vaccine and passive immunization for prevention of west nile virus encephalitis in hamster model
Emerging Infectious Diseases, 2002Co-Authors: Robert B. Tesh, Juan Arroyo, Hilda Guzman, Shu-yuan Xiao, Amelia Travassos P A Da Rosa, Thomas P. MonathAbstract:Results of experiments evaluating the efficacy of three immunization strategies for the prevention of West Nile virus (WNV) encephalitis are reported. Immunization strategies evaluated included a killed virus Veterinary Vaccine, a live attenuated chimeric virus Vaccine candidate, and passive immunization with WNVimmune serum; all were tested by using a hamster model of the disease. Each product protected the animals from clinical illness and death when challenged with a hamster-virulent wild-type WNV strain 1 month after initial immunization. The live attenuated chimeric virus Vaccine candidate induced the highest humoral antibody responses, as measured by hemagglutination inhibition, complement fixation, and plaque reduction neutralization tests. Although the duration of protective immunity was not determined in this study, our preliminary results and the cumulative experience of other virus Vaccines suggest that the live attenuated chimeric virus provides the longest lasting immunity. fter the appearance of West Nile virus (WNV) in North America and the resulting human and equine cases of
H. Van Heerden - One of the best experts on this subject based on the ideXlab platform.
-
Use of the mice passive protection test to evaluate the humoral response in goats vaccinated with Sterne 34F2 live spore Vaccine
Veterinary Research, 2017Co-Authors: P. H. Phaswana, O. C. Ndumnego, S. M. Koehler, W. Beyer, J. E. Crafford, H. Van HeerdenAbstract:AbstractThe Sterne live spore Vaccine (34F2) is the most widely used Veterinary Vaccine against anthrax in animals. Antibody responses to several antigens of Bacillus anthracis have been described with a large focus on those against protective antigen (PA). The focus of this study was to evaluate the protective humoral immune response induced by the live spore anthrax Vaccine in goats. Boer goats vaccinated twice (week 0 and week 12) with the Sterne live spore Vaccine and naive goats were used to monitor the anti-PA and toxin neutralizing antibodies at week 4 and week 17 (after the second Vaccine dose) post vaccination. A/J mice were passively immunized with different dilutions of sera from immune and naive goats and then challenged with spores of B. anthracis strain 34F2 to determine the protective capacity of the goat sera. The goat anti-PA ELISA titres indicated significant sero-conversion at week 17 after the second doses of Vaccine (p = 0.009). Mice receiving undiluted sera from goats given two doses of Vaccine (twice immunized) showed the highest protection (86%) with only 20% of mice receiving 1:1000 diluted sera surviving lethal challenge. The in vitro toxin neutralization assay (TNA) titres correlated to protection of passively immunized A/J mice against lethal infection with the Vaccine strain Sterne 34F2 spores using immune goat sera up to a 1:10 dilution (rs ≥ 0.522, p = 0.046). This study suggests that the passive mouse protection model could be potentially used to evaluate the protective immune response in livestock animals vaccinated with the current live Vaccine and new Vaccines.
